DGX Quest Diagnostics Incorporated

Bragar Eagel & Squire, P.C. Is Investigating Quest Diagnostics, Inc. (DGX) on Behalf of Patients Whose Confidential Medical Information Was Hacked and Encourages Affected Individuals to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Quest Diagnostics, Inc. (“Quest” or the “Company”) (NYSE:DGX) for the wrongful disclosure of confidential health and medical information was obtained by third-party hackers. For additional information and to assist the investigation, please visit the firm’s site: http://bespc.com/quest-diagnostics/.

On December 12, 2016, clinical laboratory services company Quest announced that it is investigating a third-party infiltration into an internet application on its network. Quest issued a press release disclosing that on November 26, 2016, an unauthorized third party accessed the MyQuest by Care 360 internet application and obtained confidential health and other information concerning approximately 34,000 patients. The information included names, dates of birth, lab results, and, in some instances, phone numbers.

Quest announced that it sent notifications to those individuals whose information was affected. Quest is working with law enforcement officials and cybersecurity firms to determine the source and cause of the breach.

Individuals who have been affected by the Quest health data breach or who have information concerning the Quest health data breach can assist the investigation by visiting the firm’s website http://bespc.com/quest-diagnostics/.

If you are aware of any facts relating to this investigation, are a user of Quest’s MyQuest by Care360 app, or believe you may have been affected by the Quest health data breach, or if you have questions concerning what rights you may have concerning the Quest health data breach, please contact David J. Stone, Esq., by email at [email protected], or by telephone at (212) 308-5858, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

EN
16/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Quest Diagnostics Incorporated

Quest Diagnostics Inc: 1 director

A director at Quest Diagnostics Inc sold 1,975 shares at 185.000USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 3 April 2025 in which we reassessed the appropriateness of the ratings in th...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings assigns Baa1 rating to Quest Diagnostics Incorporated'...

Moody's Ratings (Moodys) assigned a Baa1 rating to Quest Diagnostics Incorporated' ("Quest") proposed offering of senior unsecured notes. Quest intends to use the net proceeds from this offering to fund the recently announced acquisition of LifeLabs (a Canadian provider of community laboratory tests...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch